Wedbush analyst Robert Driscoll made no change to the firm’s Outperform rating and $12 price target on Omega Therapeutics (OMGA) after the company announced a research collaboration with Novo Nordisk (NVO) focusing on development of novel therapies targeting obesity. The firm views the collaboration as robust validation of Omega’s OEG platform in treating indications outside of oncology, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OMGA:
- Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Omega Therapeutics presents preclinical data on liver fibrosis and inflammation
